Neurologic disease associated with 17D-204 yellow fever vaccination: A report of 15 cases
Ann McMahon(United States Food and Drug Administration), Martín S. Cetron, Robert Ball(Center for Drug Evaluation and Research), Lewis Markoff, Anthony A. Marfin, Robert T. Chen(The Task Force for Global Health), Rachel B. Eidex, Michelle Russell, James J. Sejvar(Centers for Disease Control and Prevention), M. Miles Braun(Center for Biologics Evaluation and Research), Edward B. Hayes(Centers for Disease Control and Prevention)
Cited by 132
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
|Arthritis & Rheumatism|2002|661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
|Annals of Internal Medicine|2003|459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448